It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Abnormalities of ventricular action potential cause malignant cardiac arrhythmias and sudden cardiac death. Here, we aim to identify microRNAs that regulate the human cardiac action potential and ask whether their manipulation allows for therapeutic modulation of action potential abnormalities. Quantitative analysis of the microRNA targetomes in human cardiac myocytes identifies miR-365 as a primary microRNA to regulate repolarizing ion channels. Action potential recordings in patient-specific induced pluripotent stem cell-derived cardiac myocytes show that elevation of miR-365 significantly prolongs action potential duration in myocytes derived from a Short-QT syndrome patient, whereas specific inhibition of miR-365 normalizes pathologically prolonged action potential in Long-QT syndrome myocytes. Transcriptome analyses in these cells at bulk and single-cell level corroborate the key cardiac repolarizing channels as direct targets of miR-365, together with functionally synergistic regulation of additional action potential-regulating genes by this microRNA. Whole-cell patch-clamp experiments confirm miR-365-dependent regulation of repolarizing ionic current Iks. Finally, refractory period measurements in human myocardial slices substantiate the regulatory effect of miR-365 on action potential in adult human myocardial tissue. Our results delineate miR-365 to regulate human cardiac action potential duration by targeting key factors of cardiac repolarization.
An abnormal cardiac action potential underlies different types of cardiac arrhythmias. Here the authors show that microRNA-365 regulates the cardiac action potential by modulating key cardiac repolarizing channels.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details













1 Technical University of Munich (TUM), Institute of Pharmacology and Toxicology, Munich, Germany (GRID:grid.6936.a) (ISNI:0000000123222966); DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237)
2 Center for Drug Research, Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
3 DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237); University Medical Centre Mannheim, First Department of Medicine, Faculty of Medicine, Mannheim, Germany (GRID:grid.411778.c) (ISNI:0000 0001 2162 1728)
4 Technical University of Munich (TUM), Institute of Pharmacology and Toxicology, Munich, Germany (GRID:grid.6936.a) (ISNI:0000000123222966)
5 Technical University of Munich (TUM), Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Munich, Germany (GRID:grid.6936.a) (ISNI:0000000123222966)
6 DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237); Technical University of Munich (TUM), Institute of Human Genetics, Klinikum rechts der Isar, Munich, Germany (GRID:grid.6936.a) (ISNI:0000000123222966)
7 University Hospital, Ludwig-Maximilians-Universität München, Clinic of Cardiac Surgery, Munich, Germany (GRID:grid.411095.8) (ISNI:0000 0004 0477 2585)
8 University Hospital of the Ruhr-University Bochum, Erich and Hanna Klessmann Institute, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany (GRID:grid.418457.b) (ISNI:0000 0001 0723 8327)
9 DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237); Center for Drug Research, Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
10 DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237); University Hospital, Ludwig-Maximilians-Universität München, Walter-Brendel-Centre of Experimental Medicine, Munich, Germany (GRID:grid.411095.8) (ISNI:0000 0004 0477 2585)
11 Technical University of Munich (TUM), Institute of Pharmacology and Toxicology, Munich, Germany (GRID:grid.6936.a) (ISNI:0000000123222966); DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237); Fralin Biomedical Research Institute at Virginia Tech Carilion, Roanoke, USA (GRID:grid.438526.e) (ISNI:0000 0001 0694 4940)
12 DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237); Technical University of Munich (TUM), Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Munich, Germany (GRID:grid.6936.a) (ISNI:0000000123222966)